Clinical Trial Update: A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial completion evaluating Survodutide for obesity with non-alcoholic steatohepatitis (NASH) to reduce liver fat and promote weight loss.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis
• Obesity

Drugs mentioned

• Survodutide (BI456906)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Obesity, Non-Alcoholic SteatoHepatitis (NASH) | Phase 3 | Status: COMPLETED